New Data Published Demonstrates Rosetta Genomics' miRview meso is a Highly Sensitive Test for Differentiating Mesothelioma

Rosetta Genomics, Ltd.

announces that a peer reviewed article entitled "A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma" appears in the online version of "The Journal of Molecular Diagnostics." The study demonstrates the ability of the Company's miRview™ meso test to accurately differentiate malignant pleural mesothelioma (MPM) from primary and metastatic carcinomas in the lung and pleura. The study is available online at http://jmd.amjpathol.org/cgi/content/abstract/jmoldx.2010.090169v1 The study included formalin-fixed, paraffin-embedded (FFPE) samples that were explored using microRNA microarrays to identify potential biomarkers. Based on these data, a qRT-PCR platform was utilized to verify findings and develop a diagnostic assay. The clinical validation of this diagnostic assay was performed on 68 samples from the lung and pleura and achieved a sensitivity of 100% and a specificity of 94%.